Table of Contents Author Guidelines Submit a Manuscript
TheScientificWorldJOURNAL
Volume 10 (2010), Pages 1919-1931
http://dx.doi.org/10.1100/tsw.2010.182
Review Article

PSA and Beyond: The Past, Present, and Future of Investigative Biomarkers for Prostate Cancer

James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD, USA

Received 30 July 2010; Revised 4 September 2010; Accepted 7 September 2010

Academic Editor: Scott Eggener

Copyright © 2010 Jeffrey Tosoian and Stacy Loeb.

Citations to this Article [48 citations]

The following is the list of published articles that have cited the current article.

  • Janneta Tcherkassova, Carolina Abramovich, Rafael Moro, Chen Chen, Ralph Schmit, Angela Gerber, and Ricardo Moro, “Combination of CA125 and RECAF biomarkers for early detection of ovarian cancer,” Tumor Biology, vol. 32, no. 4, pp. 831–838, 2011. View at Publisher · View at Google Scholar
  • Hifzur Rahman Siddique, Shrawan Kumar Mishra, R. Jeffery Karnes, and Mohammad Saleem, “Lupeol, a novel androgen receptor inhibitor: Implications in prostate cancer therapy,” Clinical Cancer Research, vol. 17, no. 16, pp. 5379–5391, 2011. View at Publisher · View at Google Scholar
  • Michael J. Duffy, “Prostate-specific antigen: Does the current evidence support its use in prostate cancer screening?,” Annals of Clinical Biochemistry, vol. 48, no. 4, pp. 310–316, 2011. View at Publisher · View at Google Scholar
  • Sigrun Thorsteinsdottir, Thorkell Gudjonsson, Ole Haagen Nielsen, Ben Vainer, and Jakob Benedict Seidelin, “Pathogenesis and biomarkers of carcinogenesis in ulcerative colitis,” Nature Reviews Gastroenterology and Hepatology, vol. 8, no. 7, pp. 395–404, 2011. View at Publisher · View at Google Scholar
  • Bob Djavan, Amir Kazzazi, Lori Dulabon, Markus Margreiter, Alexander Farr, Markus Johannes Handl, and Herbert Lepor, “Diagnostic Strategies for Prostate Cancer,” European Urology Supplements, vol. 10, no. 3, pp. e26–e37, 2011. View at Publisher · View at Google Scholar
  • Nicholas Navin, and James Hicks, “Future medical applications of single-cell sequencing in cancer,” Genome Medicine, vol. 3, no. 5, 2011. View at Publisher · View at Google Scholar
  • B. Cvetković, V. Vučić, Z. Cvetković, T. Popović, and M. Glibetić, “Systemic alterations in concentrations and distribution of plasma phospholipids in prostate cancer patients,” Medical Oncology, vol. 29, no. 2, pp. 809–814, 2011. View at Publisher · View at Google Scholar
  • Stephan Gade, Christine Porzelius, Maria Faelth, Jan C. Brase, Daniela Wuttig, Ruprecht Kuner, Harald Binder, Holger Sueltmann, and Tim Beissbarth, “Graph based fusion of miRNA and mRNA expression data improves clinical outcome prediction in prostate cancer,” Bmc Bioinformatics, vol. 12, 2011. View at Publisher · View at Google Scholar
  • Jean-Nicolas Cornu, and Olivier Cussenot, “Reply to Giuseppe Lippi's Letter to the Editor re: Jean-Nicolas Cornu, Géraldine Cancel-Tassin, Valérie Ondet, et al. Olfactory detection of prostate cancer by dogs sniffing urine: A step forward in early diagnosis. Eur Urol 2011;59:197-201,” European Urology, vol. 60, no. 4, pp. e30, 2011. View at Publisher · View at Google Scholar
  • Scott Eggener, “Prostate Cancer,” Thescientificworldjournal, vol. 11, pp. 749–750, 2011. View at Publisher · View at Google Scholar
  • Georgios Koutalellis, Konstantinos Stravodimos, Margaritis Avgeris, Konstantinos Mavridis, Andreas Scorilas, Andreas Lazaris, and Constantinos Constantinides, “L-dopa decarboxylase (DDC) gene expression is related to outcome in patients with prostate cancer,” Bju International, vol. 110, no. 6B, pp. E267–E273, 2012. View at Publisher · View at Google Scholar
  • Ioannis Katafigiotis, Stavros I. Tyritzis, Konstantinos G. Stravodimos, Christos Alamanis, Kitty Pavlakis, Antonia Vlahou, Manousos Makridakis, Amalia Katafigioti, Spiros D. Garbis, and Constantinos A. Constantinides, “Zinc α2-glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer,” BJU International, vol. 110, no. 11b, pp. E688–E693, 2012. View at Publisher · View at Google Scholar
  • Seung Hwan Lee, Mun Su Chung, Joo Hee Kim, Young Taik Oh, Koon Ho Rha, and Byung Ha Chung, “Magnetic Resonance Imaging Targeted Biopsy in Men with Previously Negative Prostate Biopsy Results,” Journal of Endourology, vol. 26, no. 7, pp. 787–791, 2012. View at Publisher · View at Google Scholar
  • A. T. Wild, T. L. DeWeese, J. Zeng, T. Salih, J. M. Herman, K. Aziz, S. Chettiar, R. Kumar, R. K. Hales, R. P. Gajula, N. Gandhi, D. Y. Song, and P. T. Tran, “Tissue Biomarkers for Prostate Cancer Radiation Therapy,” Current Molecular Medicine, vol. 12, no. 6, pp. 772–787, 2012. View at Publisher · View at Google Scholar
  • Georgios Koutalellis, Konstantinos Stravodimos, Margaritis Avgeris, Konstantinos Mavridis, Andreas Scorilas, Andreas Lazaris, and Constantinos Constantinides, “ L-dopa decarboxylase ( DDC ) gene expression is related to outcome in patients with prostate cancer ,” BJU International, vol. 110, no. 6b, pp. E267–E273, 2012. View at Publisher · View at Google Scholar
  • H Ballentine Carter, “Differentiation of lethal and non lethal prostate cancer: PSA and PSA isoforms and kinetics,” Asian Journal of Andrology, vol. 14, no. 3, pp. 355–360, 2012. View at Publisher · View at Google Scholar
  • José A. Pereira, Tiago Bilhim, Marisa Duarte, Hugo Rio Tinto, Lúcia Fernandes, and João Martins Pisco, “Patient Selection and Counseling before Prostatic Arterial Embolization,” Techniques in Vascular and Interventional Radiology, vol. 15, no. 4, pp. 270–275, 2012. View at Publisher · View at Google Scholar
  • Po-Yuan Lin, Kai-Lun Cheng, James D. McGuffin-Cawley, Fuh-Sheng Shieu, Anna C. Samia, Sanjay Gupta, Matthew Cooney, Cheryl L. Thompson, and Chung Chiun Liu, “Detection of alpha-methylacyl-CoA racemase (AMACR) A biomarker of prostate cancer, in patient blood samples using a nanoparticle electrochemical biosensor,” Biosensors, vol. 2, no. 4, pp. 377–387, 2012. View at Publisher · View at Google Scholar
  • Masayasu Mie, Tetsuro Kai, Thao Le, Anthony E. G. Cass, and Eiry Kobatake, “Selection of DNA Aptamers with Affinity for Pro-gastrin-Releasing Peptide (proGRP), a Tumor Marker for Small Cell Lung Cancer,” Applied Biochemistry and Biotechnology, vol. 169, no. 1, pp. 250–255, 2012. View at Publisher · View at Google Scholar
  • O'Hanlon Brown, and Waxman, “Current management of prostate cancer: Dilemmas and trials,” British Journal of Radiology, vol. 85, no. 1, pp. S28–S40, 2012. View at Publisher · View at Google Scholar
  • Jeong S. Han, Adam D. Toll, Ali Amin, H. Ballentine Carter, Patricia Landis, Stephen Lee, and Jonathan I. Epstein, “Low Prostate-specific Antigen and No Gleason Score Upgrade Despite More Extensive Cancer During Active Surveillance Predicts Insignificant Prostate Cancer at Radical Prostatectomy,” Urology, vol. 80, no. 4, pp. 883–888, 2012. View at Publisher · View at Google Scholar
  • J. Gumulec, M. Masarik, S. Krizkova, M. Hlavna, P. Babula, R. Hrabec, A. Rovny, M. Masarikova, J. Sochor, V. Adam, T. Eckschlager, and R. Kizek, “Evaluation of alpha-methylacyl-CoA racemase, metallothionein and prostate specific antigen as prostate cancer prognostic markers,” Neoplasma, vol. 59, no. 2, pp. 191–200, 2012. View at Publisher · View at Google Scholar
  • Kathleen Gabriel, Alistair Ingram, Richard Austin, Anil Kapoor, Damu Tang, Fadwa Majeed, Talha Qureshi, and Khalid Al-Nedawi, “Regulation of the Tumor Suppressor PTEN through Exosomes: A Diagnostic Potential for Prostate Cancer,” PLoS ONE, vol. 8, no. 7, 2013. View at Publisher · View at Google Scholar
  • Christopher Whelan, Mark Kawachi, David D. Smith, Jennifer Linehan, Gail Babilonia, Rosa Mejia, Timothy Wilson, and Steven S. Smith, “Expressed Prostatic Secretion Biomarkers Improve Stratification of National Comprehensive Cancer Network Active Surveillance Candidates: Performance of Secretion Capacity and TMPRSS2:ERG Models,” The Journal of Urology, 2013. View at Publisher · View at Google Scholar
  • Jeffrey J. Tosoian, Eric JohnBull, Bruce J. Trock, Patricia Landis, Jonathan I. Epstein, Alan W. Partin, Patrick C. Walsh, and H. Ballentine Carter, “Pathological Outcomes in Men with Low Risk and Very Low Risk Prostate Cancer: Implications on the Practice of Active Surveillance,” The Journal of Urology, 2013. View at Publisher · View at Google Scholar
  • Kristina A. Matkowskyj, Zongming E. Chen, M. Sambasiva Rao, and Guang-Yu Yang, “Dysplastic Lesions in Inflammatory Bowel Disease: Molecular Pathogenesis to Morphology,” Archives of Pathology & Laboratory Medicine, vol. 137, no. 3, pp. 338–350, 2013. View at Publisher · View at Google Scholar
  • Alisa J Prager, Cynthia R Peng, Elena Lita, Debbie McNally, Aradhana Kaushal, Mary Sproull, Kathryn Compton, William L Dahut, William D Figg, Deborah Citrin, and Kevin A Camphausen, “ Urinary a HGF, IGFBP3 and OPN as diagnostic and prognostic biomarkers for prostate cancer ,” Biomarkers in Medicine, vol. 7, no. 6, pp. 831–841, 2013. View at Publisher · View at Google Scholar
  • E. Nna, “The end of the road for prostate specific antigen testing,” Nigerian Journal of Clinical Practice, vol. 16, no. 4, pp. 407–417, 2013. View at Publisher · View at Google Scholar
  • C. F. Ng, Peter K. F. Chiu, N. Y. Lam, H. C. Lam, Kim W. M. Lee, and Simon S. M. Hou, “The Prostate Health Index in predicting initial prostate biopsy outcomes in Asian men with prostate-specific antigen levels of 4–10 ng/mL,” International Urology and Nephrology, 2013. View at Publisher · View at Google Scholar
  • M. Aalberts, T. A. E. Stout, and W. Stoorvogel, “Prostasomes: extracellular vesicles from the prostate,” Reproduction, vol. 147, no. 1, pp. R1–R14, 2013. View at Publisher · View at Google Scholar
  • Elif Bilgin Doğru, Yavuz Dizdar, Ece Akşit, Feyyaz Ural, Öner Şanlı, and Vildan Yasasever, “EMMPRIN and ADAM12 in prostate cancer: preliminary results of a prospective study,” Tumor Biology, 2014. View at Publisher · View at Google Scholar
  • Shabarni Gupta, Apoorva Venkatesh, Sandipan Ray, and Sanjeeva Srivastava, “Challenges and prospects for biomarker research: A current perspective from the developing world,” Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2014. View at Publisher · View at Google Scholar
  • V. Vlaeminck-Guillem, “Le test urinaire PCA3 : quelles perspectives ?,” Médecine Nucléaire, 2014. View at Publisher · View at Google Scholar
  • Alessio Cannistraci, Anna Laura Di Pace, Ruggero De Maria, and Désirée Bonci, “MicroRNA as New Tools for Prostate Cancer Risk Assessment and Therapeutic Intervention: Results from Clinical Data Set and Patients’ Samples,” BioMed Research International, vol. 2014, pp. 1–17, 2014. View at Publisher · View at Google Scholar
  • Sung Kyu Hong, “Kallikreins as Biomarkers for Prostate Cancer,” BioMed Research International, vol. 2014, pp. 1–10, 2014. View at Publisher · View at Google Scholar
  • Petra Leidinger, Andreas Keller, Lisa Milchram, Christian Harz, Martin Hart, Angelika Werth, Hans-Peter Lenhof, Andreas Weinhaeusel, Bastian Keck, Bernd Wullich, Nicole Ludwig, and Eckart Meese, “Combination of Autoantibody Signature with PSA Level Enables a Highly Accurate Blood-Based Differentiation of Prostate Cancer Patients from Patients w,” Plos One, vol. 10, no. 6, 2015. View at Publisher · View at Google Scholar
  • Mohammed Alshalalfa, Mark Schliekelman, Heesun Shin, Nicholas Erho, and Elai Davicioni, “Evolving transcriptomic fingerprint based on genome-wide data as prognostic tools in prostate cancer,” Biology of the Cell, 2015. View at Publisher · View at Google Scholar
  • Kara N. Babaian, “Active surveillance for prostate cancer: when to recommend delayed intervention,” Asian Journal Of Andrology, vol. 17, no. 6, pp. 885–887, 2015. View at Publisher · View at Google Scholar
  • Katrin Schlack, Laura-Maria Krabbe, Manfred Fobker, Andres Schrader, Axel Semjonow, and Martin Boegemann, “Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer,” International Journal of Molecular Sciences, vol. 17, no. 9, pp. 1520, 2016. View at Publisher · View at Google Scholar
  • Melinda M. Smits, Michael E. Wright, Jordy J. Hsiao, Brandon H. Ng, and Jinhee Lee, “Discovery proteomics identifies a molecular link between the coatomer protein complex I and androgen receptor-dependent transcription,” Journal of Biological Chemistry, vol. 291, no. 36, pp. 18818–18842, 2016. View at Publisher · View at Google Scholar
  • Bert W. O’Malley, Lindsey S. Trevino, Jianjun Shen, Charles E. Foulds, Quan Wang, Ali Shilatifard, Cheryl L. Walker, Rebecca Lee Yean Wong, Mario Medvedovic, Jing Chen, Shuk-Mei Ho, and Cristian Coarfa, “Reprogramming of the epigenome by MLL1 links early-life environmental exposures to prostate cancer risk,” Molecular Endocrinology, vol. 30, no. 8, pp. 856–871, 2016. View at Publisher · View at Google Scholar
  • Shannon T. Knuth, Michael Gildea, Kenneth Kernen, Joan Aurich-Costa, Rima Tinawi-Aljundi, Joshua Khal, Jason Hafron, and Robert Di Loreto, “Minimally invasive prostate cancer detection test using FISH probes,” Research and Reports in Urology, vol. 8, pp. 105–111, 2016. View at Publisher · View at Google Scholar
  • Jeffrey J. Tosoian, Ashley E. Ross, Lori J. Sokoll, Alan W. Partin, and Christian P. Pavlovich, “Urinary Biomarkers for Prostate Cancer,” Urologic Clinics of North America, vol. 43, no. 1, pp. 17–38, 2016. View at Publisher · View at Google Scholar
  • Amalia Katafigioti, Ioannis Katafigiotis, Stavros Sfoungaristos, Christos Alamanis, Konstantinos Stravodimos, Ioannis Anastasiou, Eleni Roumelioti, Mordechai Duvdevani, and Constantinos Constantinides, “In the search of novel urine biomarkers for the early diagnosis of prostate cancer. Intracellular or secreted proteins as the target group? Where and how to search for possible biomarkers useful in the everyday clinical practice,” Archivio Italiano di Urologia e Andrologia, vol. 88, no. 3, pp. 195–200, 2016. View at Publisher · View at Google Scholar
  • Paula Intasqui, Ricardo P. Bertolla, and Marcus Vinicius Sadi, “Prostate cancer proteomics: clinically useful protein biomarkers and future perspectives,” Expert Review of Proteomics, pp. 1–15, 2017. View at Publisher · View at Google Scholar
  • Benjamin A. Sherer, Krishnan Warrior, Karl Godlewski, Martin Hertl, Oyedolamu Olaitan, Ajay Nehra, and Leslie Allan Deane, “Prostate cancer in renal transplant recipients,” International braz j urol, vol. 43, no. 6, pp. 1021–1032, 2017. View at Publisher · View at Google Scholar
  • Vincent Fradet, Paul Toren, Molière Nguile-Makao, Michele Lodde, Jérome Lévesque, Caroline Léger, André Caron, Alain Bergeron, Tal Ben-Zvi, Louis Lacombe, Frédéric Pouliot, Rabi Tiguert, Thierry Dujardin, and Yves Fradet, “Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with low-risk prostate cancer receiving 5α-reductase inhibitors,” BJU International, 2017. View at Publisher · View at Google Scholar
  • J J Tosoian, S C Druskin, D Andreas, P Mullane, M Chappidi, S Joo, K Ghabili, J Agostino, K J Macura, H B Carter, E M Schaeffer, A W Partin, L J Sokoll, and A E Ross, “Use of the Prostate Health Index for detection of prostate cancer: results from a large academic practice,” Prostate Cancer and Prostatic Diseases, 2017. View at Publisher · View at Google Scholar